In B16-F10 melanoma models, CCL25 delivery significantly improved the proportion of infiltrating CD8+ and CCR9+CD8+ T cells on days 3, 6, and 9 following intratumoral hydrogel injection. The gene discussed is CD8A; the disease is melanoma.